The antiviral efficacy of interferons (IFNs) was evaluated using a vaccinia intranasal infection model in mice in this study. We provide evidence that intranasal administration of IFN-K and IFN-Q (days 31 to +3) resulted in 100 and 90% survival against a lethal respiratory vaccinia infection (8 LD 50 ) in mice, respectively; whereas no animals in the placebo group survived through the study period (21 days). The IFN treatment consisted of a single daily dose of 5U10 3 U per mouse for 5 consecutive days. The efficacy of IFN-Q was evident even when the IFN-Q treatments started 1^2 days after infection and when a lower dose (2U10 3 U per mouse) was used. The treatment of IFN-K and IFN-Q reduced the virus titers in the lungs of infected mice by 1000^10 000-fold, when the administration started 1 day after infection. Our data suggest that IFN-K and IFN-Q are effective in protecting vaccinia-infected mice from viral replication in lungs and mortality, and may be beneficial in other human orthopoxvirus infections.
Introduction
Smallpox and monkeypox are among the most dangerous potential bioterrorism agents [1] . Currently, there is no approved treatment for smallpox ; vaccination is the only e¡ective means for pre-and post-exposure prophylaxis for smallpox (if administered within 4 days of exposure) [2] . However, post-vaccination complications have been reported in a small percentage of people, especially those with immunode¢ciencies and eczema [1] . Poxviruses may also be genetically engineered to resist current therapies and evade vaccine-induced immunity. In light of the bioweapon potential of smallpox and monkeypox, the search for ways to treat smallpox and monkeypox is especially important.
Poxviruses are sensitive to interferon (IFN)-K/L and IFN-Q in vivo, as mice lacking IFN-K/L or IFN-Q receptor are highly susceptible to poxvirus infections [3, 4] . In mice, monkeys, or humans, IFN-K and IFN-Q have been demonstrated to have prophylactic e¡ect against various viruses such as Rift Valley fever (RVF) virus [5] and hepatitis C virus [6] . Crude IFN-K/L and recombinant IFN-Q e¡ectively reduced lesion formation in a vaccinia tail lesion model [7] . In this report we demonstrate that IFN-K and IFN-Q are e¡ective in protecting vaccinia-infected mice from viral replication in lungs and mortality, and that they may be bene¢cial in treating other human orthopoxvirus infections.
Materials and methods

Viruses and cells
The WR strain of vaccinia virus (VV) (ATCC #VR-119) was purchased from ATCC (Manassas, VA, USA), propagated in human cervical adenocarcinoma HeLa cells (ATCC #CTL-2.2), and titrated on African green monkey kidney BS-C-1 cells (ATCC #CCL-26) as previously described [8, 9] . BS-C-1 and HeLa cells were maintained in Eagle's minimal essential medium (MEM) supplemented with 10% fetal bovine serum (FBS), 100 units (U) ml 31 of penicillin, and 100 Wg ml 31 of streptomycin (Gibco-BRL, Rockville, MD, USA). All tissue culture media and phosphorus-bu¡ered solution (PBS) were purchased from Gibco-BRL.
Compounds
Recombinant murine IFN-KA (4.8U10 7 U mg 31 ) and IFN-Q (4.28U10 6 U mg 31 ) were purchased from BioSource International, Inc. (Camarillo, CA, USA) and prepared in PBS/0.1% bovine serum albumin (BSA) immediately prior to use.
Animals
Female BALB/c mice (5-week-old) were purchased from Charles River Laboratories (Wilmington, MA, USA) and quarantined 1 week prior to use. Female, 15^18 g, BALB/c mice were used in the virus challenge and IFN treatment experiments. Each experimental group was composed of 10 or 20 animals.
Intranasal challenge with virus and administration with IFN
BALB/c mice were infected intranasally with VV (1U10 5 plaque-forming units (PFU) per mouse) in a volume of 20 Wl per mouse following anesthesia with Avertin (intraperitoneally (i.p.), 0.4^0.6 mg kg 31 ) [10] . A single stock of VV was used for all experiments. The mice were treated intranasally with IFN-K (2^5U10 3 U), IFN-Q (25 U10 3 U), or PBS/0.1% BSA (placebo) in a 20-Wl volume following anesthesia with Avertin. For 21 days, the animals were monitored daily for mortality and weighed every 2^3 days.
Determination of lung virus titers
The lungs of mice (three mice per group) were taken aseptically on day 6, weighed, frozen at 370 ‡C, homogenized in MEM-2.5, brie£y sonicated, and centrifuged at low speed [11] before plaque assay on BS-C-1 [9] . The virus titers in lungs were expressed as log 10 (PFU g 31 ).
Statistical analysis
Statistical analyses were performed to compare the treated and placebo groups by two-tailed analyses. Survival curves were created by the Kaplan^Meier method using GraphPad Prism 0 4 software, and compared using the Mantel^Haeszel logrank test [12] . Fisher's exact test was used to compare the survivors in the placebo and the treated groups. Student's t-test was used to determine if there was a signi¢cant di¡erence in the body weight of the mouse and virus titers between the treated and the placebo groups. The P values less than 0.05 were considered statistically signi¢cant.
Results
Intranasal challenge
We successfully tested the respiratory infection model of VV in mice [13, 11] . The LD 50 of our virus stock was 10 4:1 PFU per mouse using the Reed^Meunch test [14] . Intranasal inoculation of 8 LD 50 (1U10 5 PFU) of VV resulted in 90^100% mortality of BALB/c mice (6-week-old), depending on the batch of mice. As demonstrated by Smee et al., [11] intranasal challenge of BALB/c mice with VV results in pneumonia, remarkable weight loss and death. The infected mice displayed the ru¥ed furs, arched backs, reduced mobility, and signi¢cant weight loss, that are typical symptoms of vaccinia infection [13] .
Pre-exposure prophylactic administration of IFNs
We ¢rst examined whether IFN treatment beginning before virus infection is e¡ective against the lethal respiratory poxvirus infections. We chose to test this treatment using intranasal administration as this route is the most practical and likely to be employed in the treatment of large civilian and military populations in the event of a bioterrorist attack. Our IFN treatment consisted of a single daily dose for 5 consecutive days, starting 1 day before the viral infection. Intranasal administration of IFN-K (5U10 3 U per mouse) and IFN-Q (5U10 3 U per mouse) resulted in animal survival rates of 100 and 90%, respectively (Fig. 1) . In contrast, no mice in the placebo survived the virus challenge. Doubling the doses of IFN-K and IFN-Q did not result in a signi¢cant increase in survival rates ( þ 5%, data not shown). The IFN treatments did not signi¢cantly reduce weight loss (10^12%) on day 6 compared to the placebo, although the treated mice regained weight thereafter (Fig. 2) .
E¡ect of start time of IFN-Q treatment
We then studied the e¡ects of delayed treatment of IFN-Q on antiviral e⁄cacy. A 100% survival rate was obtained when the ¢ve daily treatments were initiated 1 day before or the day of infection (Table 1) . Starting the treatments on days +1, +2, and +3 resulted in 90, 70, and 50% survival rates, respectively. In this study, a 10% survival rate was found in the placebo. We observed a signi¢cantly higher survival rate in mice treated 2 days after infection compared to the placebo. There was no signi¢cant di¡er-ence between day 0 and +1; however, the survival rate following day +2 treatment was signi¢cantly lower than that following day 0 treatment. Therefore, we chose to start treatment at day +1, although the di¡erence between day +1 and +2 was not signi¢cant.
E¡ect of IFN treatment on lung virus titers
Next, we studied the e¡ect of IFN treatment on virus replication in lung tissues. The lung virus titers in the treated mice were 1000^10 000-fold lower than that in placebo (P 6 0.05, Fig. 3 ), indicating that IFN-K and IFN-Q are e¡ective in suppressing vaccinia replication in the lungs of infected mice when the treatment is started 1 day after infection.
E⁄cacy of lower doses of IFN-K and IFN-Q
We further examined the e⁄cacy of lower doses of IFNs. We observed an 80% survival rate when 2000 U of IFN-Q was used, compared to the 90% survival that resulted from the 5000 U of IFN-Q-treated group; however, the di¡erence was not statistically signi¢cant. In contrast, only 10% of the animals in placebo survived the vaccinia infection. When a lower dose of IFN-K (2000 U) was used, only 40% survival rate was seen compared to 90^100% survival when 5000 U of IFN-K was used.
Discussion
We demonstrate that intranasal administration of IFN-K and IFN-Q can reduce lung virus titers and mortality due to respiratory vaccinia infection in mice. VV is sensitive to IFNs in vivo, as mice lacking IFN-K/L or IFN-Q receptor are highly susceptible to poxvirus infections [15] . This is consistent with previous reports that vaccinia tail lesions were reduced greatly by ¢ve i.p. administrations of crude IFN within 24 h prior to infection [16] . Monkeys treated with daily intramuscularly (i.m.) or intravenous (i.v.) injections of leukocyte IFN (5U10 5 U kg 31 ) from day 31 to day +7 after vaccination were completely protected and the severity of the skin lesions was decreased. Lesion scores correlated inversely with the dose of IFN [17] . IFN-K is also e¡ective against other viruses in mice and monkeys, such as St. Louis encephalitis virus [18] , Venezuelan equine encephalitis (VEE) virus [19] , and RVF virus [5] .
The dose of recombinant murine IFN used (5U10 3 U) approximates that used in previous studies [20^22] . No apparent toxic e¡ects were observed in mice that received a single daily intranasal dose of IFN-K (1U10 4 U) or IFN-Q (1U10 4 U) for 5 consecutive days as judged by insigni¢cant weight loss and mobility reduction (data not shown). We chose an IFN regime consisting of a single daily intranasal dose (5U10 3 U) for 5 days because it provided the best protection without apparent toxic e¡ects according to our preliminary and published work. The virus challenge dose (8 LD 50 or 10 5 PFU) used in this study was moderate. Further studies are necessary to clarify the e⁄cacy of IFNs against severe orthopoxvirus infections using 100 LD 50 of VV.
The mechanisms by which IFNs prevent mortality resulting from vaccinia infection are not completely understood. One possible explanation for the reduced mortality in IFN-treated mice may be that VV replication is inhibited as a consequence of the direct antiviral e¡ect of IFNs. VV titers in lungs of IFN-K-and IFN-Q-treated mice were reduced relative to titers in the placebo mice by approximately 3^4 log, which may account for the observed reduction in mortality. IFN-K/L and IFN-Q can induce an antiviral state by triggering the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway and eventually by inducing the 2P,5P-oligoadenylate synthetase (OAS)/RNase L and dsRNA-dependent protein kinase (PKR) [23, 24] . In addition, IFNs regulate immune responses mediated by e¡ector cells such as natural killer (NK) cells, macrophages, and cytolytic T lymphocytes (CTL) [25] .
The e⁄cacy of IFN-Q has been evaluated in a variety of experimental infections, such as cytomegalovirus (CMV) infections in mice and rats [26, 27] . Pretreatment of mice with anti-IFN-Q delayed LCMV elimination [28] , increased mortality in mouse hepatitis virus (MHV)3-infected mice [29, 30] , and enhanced the spread of murine ectromelia virus to and replication in the spleen, lungs, ovaries and livers [31] . Morrill and his colleagues demonstrated that prophylactic treatment of rhesus macaques with recombinant IFN-Q (10 4^1 0 6 U, i.m., days 31 to +3) reduced viremia and diminished the signs of RVF [32] . IFN-Q can enhance the overall development of cell-mediated immune responses, macrophage activation, antigen presentation, and chemokine gene expression, direct antiviral effect, and induction of NO-mediated antiviral activity by macrophages [33, 34] , and regulation of IFN-K/L production [24] . This supports the fact that the in vivo e⁄cacy of IFNs tends to be higher when the IFN administration starts before the infection, allowing the e¡ects of IFNs to have a 'head start' on the host cells during the race between virus replication and IFN activity. Taken together, both innate and adaptive immune responses are likely to play important roles in this IFN-induced antiviral effect.
Our data show that post-exposure IFN-Q treatment is e¡ective against lethal vaccinia infection in mice. Previous reports showed that IFNs are e¡ective against viral infections in animals usually when they are given prior to the infection. Pegynated IFN-K (0.4^5 U10 5 U per mouse, i.p., days 32 to +5) was shown to be e¡ective against aerosolized VEE virus [19] . Treatment of mice with IFN-Q prior to infection (324 h and 34 h, i.p. or i.m.) with murine CMV (MCMV) signi¢cantly reduced mortality in a dose-dependent manner; whereas IFN-Q administered after MCMV infection had no apparent e¡ect [26] . Prophylactic IFN treatment may be clinically useful in some viral infections where exposure to the virus can be predicted; however, post-exposure IFN-Q treatment would be more useful in antiviral therapy.
Our initial experiments demonstrate that IFN-K is slightly, but not signi¢cantly, more e¡ective than IFN-Q in suppressing virus replication in lungs (Fig. 3) and virus-induced weight loss (Fig. 2) ; however, IFN-Q appears to be more e¡ective when the treatment was delayed and a lower dose was used. IFN-Q has been suggested to replace IFN-K/L as it appears to be less toxic than IFN-K [35] . In addition, we found IFN-Q, but not IFN-K, enhanced the in vivo anti-poxviral e⁄cacy of other antiviral drugs (data not shown). As smallpox vaccination can cause serious complications in immunocompromised individuals and as poxvirus infection can cause an immunosuppressive e¡ect [1] , prophylactic treatment using IFN-Q may have greater e⁄cacy than IFN-K. For these reasons, our further studies thus will focus on the IFN-Q application in control of poxvirus infection in mice.
Based on the above results, we concluded that intranasal administration of IFN-Q could be e¡ective against poxvirus infection even when treatment is delayed and when a lower dose (2000 U) is used. Recombinant human IFN-Q (Actimmune 0 , Genentech, Inc.) has been approved to treat chronic granulomatous disease, a rare genetic disorder characterized by de¢cient phagocyte oxidative metabolism [36, 37] . The Actimmune (IFN-Q1L) is recommended to be administered subcutaneously three times weekly (1.5U10 6 U m 32 ). To our knowledge, bene¢cial e¡ects of post-exposure IFN-Q treatment have not been reported. Here, we provide the ¢rst evidence that IFN-Q can be used as an anti-poxviral post-exposure prophylaxis. Our data thus extend the application of this biological response modi¢er to control of poxvirus infection. IFNs and IFN inducers may also be bene¢cial in reduction of vaccine-induced in£ammatory e¡ects. For instance, simultaneous immunization and treatment of monkeys with IFN-K/L or IFN inducers induced immunity, prevented viremia, and lessened local in£ammatory reactions caused by the vaccination [38] . Intranasal administration of IFN-K and IFN-Q provides nearly full protection against respiratory VV infection in mice; therefore, our results have implications in the utilization of IFN as a prophylactic tool on a scenario of aerosol smallpox and monkeypox.
